Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases Abstract #2843

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up
Aim(s): A retrospective analyze of characteristics of the adult population at a single center and correlation with overall survival (OS), Disease-Free Survival (DFS), and Progression-Free Survival (PFS)
Materials and methods: We selected patients from the pathology databases; all cases were re-classified according to the 2017 WHO criteria. The lab, clinical parameters and treatment strategy were gathered from the record. The patients were evaluated with CT/MRI scans every 3-6 months during the first 5 years and 6-12 months thereafter. We use PFS, OS, and DFS as the outcome measures. Univariate analysis of the prognosis factors, the Kaplan–Meier method and log-rank test were used.Fig1.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Deyanira González Devia

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result